Positive Ascites Cytology, Postoperative Chemotherapy and Prognosis of Stage I Ovarian Clear Cell Carcinoma. 2023

Michiko Kubo-Kaneda, and Eiji Kondo, and Toshiharu Okugawa, and Takaharu Yamawaki, and Toru Hirata, and Makoto Tsuji, and Kenji Nagao, and Maya Kato, and Koichi Yoshimura, and Tomoaki Ikeda
Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Japan.

OBJECTIVE Ovarian clear cell carcinoma (CCC) is associated with a poor prognosis and is resistant to chemotherapy. The aim of this study was to investigate the prognosis of CCC in Mie prefecture and to identify poor prognostic factors. METHODS In this multi-center retrospective study, we analyzed the data of patients with CCC between February 2012 and December 2020. Patients were staged according to the International Federation of Gynecology and Obstetrics (FIGO) 2014 system. Statistical analyses were performed using the Kaplan-Meier method and compared between the two groups using the log-rank test. RESULTS A total of 112 patients were included and the median follow-up time was 48 months. There was no difference in the prognosis between stages IA, IC1, and IC2. For patients at stages IA, IC1, and IC2, there was no difference in progression-free survival (PFS) and overall survival between the adjuvant chemotherapy and no chemotherapy groups. Median postrecurrent survival was 18 and 20 months in the stages I-II and III-IV groups, respectively. Multivariate analysis revealed that positive ascites cytology (p=0.006) was associated with PFS for patients at stages I-II and that the stage (p=0.039) was associated with PFS for patients at stages III-IV. CONCLUSIONS Positive ascites cytology was a poor prognostic factor for patients at an early stage of CCC. Postoperative chemotherapy could be omitted for patients in stages IA and IC1. Relapsed patients did not respond to the standard treatment and had a poor prognosis regardless of the primary stage.

UI MeSH Term Description Entries
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077216 Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer. Epithelial Ovarian Cancer,Epithelial Ovarian Carcinoma,Ovarian Cancer, Epithelial,Ovarian Epithelial Cancer,Ovarian Epithelial Carcinoma,Cancer, Epithelial Ovarian,Cancer, Ovarian Epithelial,Carcinoma, Epithelial Ovarian,Epithelial Cancer, Ovarian,Epithelial Carcinoma, Ovarian,Epithelial Ovarian Cancers,Epithelial Ovarian Carcinomas,Ovarian Carcinoma, Epithelial,Ovarian Epithelial Cancers,Ovarian Epithelial Carcinomas
D000093222 Cytology The study of single cell as a unit of living organisms. Cytopathology, a branch of this discipline, studies structural changes of cells in diseases and is used in diagnosing diseases. Cytopathology,Cytopathologies
D001201 Ascites Accumulation or retention of free fluid within the peritoneal cavity.
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D017024 Chemotherapy, Adjuvant Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Chemotherapy,Drug Therapy, Adjuvant,Adjuvant Drug Therapy

Related Publications

Michiko Kubo-Kaneda, and Eiji Kondo, and Toshiharu Okugawa, and Takaharu Yamawaki, and Toru Hirata, and Makoto Tsuji, and Kenji Nagao, and Maya Kato, and Koichi Yoshimura, and Tomoaki Ikeda
October 2017, Gynecologic oncology,
Michiko Kubo-Kaneda, and Eiji Kondo, and Toshiharu Okugawa, and Takaharu Yamawaki, and Toru Hirata, and Makoto Tsuji, and Kenji Nagao, and Maya Kato, and Koichi Yoshimura, and Tomoaki Ikeda
July 2018, Gynecologic oncology,
Michiko Kubo-Kaneda, and Eiji Kondo, and Toshiharu Okugawa, and Takaharu Yamawaki, and Toru Hirata, and Makoto Tsuji, and Kenji Nagao, and Maya Kato, and Koichi Yoshimura, and Tomoaki Ikeda
September 2012, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Michiko Kubo-Kaneda, and Eiji Kondo, and Toshiharu Okugawa, and Takaharu Yamawaki, and Toru Hirata, and Makoto Tsuji, and Kenji Nagao, and Maya Kato, and Koichi Yoshimura, and Tomoaki Ikeda
January 2020, International journal of environmental research and public health,
Michiko Kubo-Kaneda, and Eiji Kondo, and Toshiharu Okugawa, and Takaharu Yamawaki, and Toru Hirata, and Makoto Tsuji, and Kenji Nagao, and Maya Kato, and Koichi Yoshimura, and Tomoaki Ikeda
January 2002, Acta cytologica,
Michiko Kubo-Kaneda, and Eiji Kondo, and Toshiharu Okugawa, and Takaharu Yamawaki, and Toru Hirata, and Makoto Tsuji, and Kenji Nagao, and Maya Kato, and Koichi Yoshimura, and Tomoaki Ikeda
April 2020, Gynecologic oncology,
Michiko Kubo-Kaneda, and Eiji Kondo, and Toshiharu Okugawa, and Takaharu Yamawaki, and Toru Hirata, and Makoto Tsuji, and Kenji Nagao, and Maya Kato, and Koichi Yoshimura, and Tomoaki Ikeda
January 2022, Frontiers in oncology,
Michiko Kubo-Kaneda, and Eiji Kondo, and Toshiharu Okugawa, and Takaharu Yamawaki, and Toru Hirata, and Makoto Tsuji, and Kenji Nagao, and Maya Kato, and Koichi Yoshimura, and Tomoaki Ikeda
November 2017, Journal of gynecologic oncology,
Michiko Kubo-Kaneda, and Eiji Kondo, and Toshiharu Okugawa, and Takaharu Yamawaki, and Toru Hirata, and Makoto Tsuji, and Kenji Nagao, and Maya Kato, and Koichi Yoshimura, and Tomoaki Ikeda
June 2021, Diagnostic cytopathology,
Michiko Kubo-Kaneda, and Eiji Kondo, and Toshiharu Okugawa, and Takaharu Yamawaki, and Toru Hirata, and Makoto Tsuji, and Kenji Nagao, and Maya Kato, and Koichi Yoshimura, and Tomoaki Ikeda
September 2017, Gynecologic oncology,
Copied contents to your clipboard!